ArticleAntimicrobial agents and chemotherapy2018
Development of Echinocandin Resistance in Candida tropicalis following Short-Term Exposure to Caspofungin for Empiric Therapy.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- From Species Identification to Empirical Therapy: A Machine Learning and Rule-Based Decision Support Framework for Antifungal Resistance Prediction in ICUMedical sciences (Basel, Switzerland) · 2026Article
- Draft genome sequences of two clinical isolates ofMicrobiology resource announcements · 2026Article
- Changing Climate, ChangingJournal of fungi (Basel, Switzerland) · 2025Review
- Emergence of Flucytosine-Resistant Candida tropicalis Clade, the Netherlands.Emerging infectious diseases · 2025Article
- The multidrug-resistantCurrent research in microbial sciences · 2025Review
- Fighting Emerging Caspofungin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Genetic Mutations in FKS1 Gene Associated with Acquired Echinocandin Resistance in Candida parapsilosis Complex.Mycopathologia · 2024Article
- Time to positivity of blood cultures causing candidemia and its relation to mortality.Iranian journal of microbiology · 2024Article
- First Report of Azole-ResistantJournal of fungi (Basel, Switzerland) · 2023Article
- Short Tandem Repeat Genotyping and Antifungal Susceptibility Testing of Latin AmericanJournal of fungi (Basel, Switzerland) · 2023Article
- Molecular fingerprinting by multi-locus sequence typing identifies microevolution and nosocomial transmission ofFrontiers in public health · 2023Article
- Design of a multi-epitope vaccine against the pathogenic fungi Candida tropicalis using an in silico approach.Journal, genetic engineering & biotechnology · 2022Article
- Fatal Breakthrough Candidemia in an Immunocompromised Patient in Kuwait Due toJournal of fungi (Basel, Switzerland) · 2022Article
- The emerging threat antifungal-resistantFrontiers in fungal biology · 2022Review
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.Drugs · 2021Review
- Mechanisms of Candida Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics.Probiotics and antimicrobial proteins · 2021Review
- Review
- Prevalence and antifungal drug resistance of nosocomialCurrent medical mycology · 2021Article
- Continual Decline in Azole Susceptibility Rates inFrontiers in microbiology · 2021Article
- Case Report: Echinocandin-ResistanceFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolation of two echinocandin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.